Overview
Male breast cancer is a rare malignant disease that arises in the breast tissue of men. Although much less common than female breast cancer, it follows many of the same biological principles and can present similarly. Because awareness is lower and routine screening is uncommon in men, diagnosis is frequently delayed. Reliable general information can be found via clinical resources such as patient information sites.
Signs and initial evaluation
Common early signs include a painless lump beneath or near the nipple, changes to the skin or nipple (retraction, ulceration, or discharge), and enlargement of nearby lymph nodes. Any persistent breast change in a man warrants clinical assessment. Typical diagnostic steps include a focused physical examination, imaging (mammography and/or ultrasound), and tissue sampling by core needle biopsy or excisional biopsy to establish a definitive diagnosis.
Causes and risk factors
Multiple factors influence the risk of developing breast cancer in men. Genetic predisposition, particularly mutations in BRCA genes, is an important contributor. Hormonal imbalances that raise estrogen activity, previous exposure to ionizing radiation, chronic liver disease, obesity, and certain testicular conditions can also increase risk. For information on breast anatomy relevant to disease origin, see breast tissue overview.
- Inherited mutations (for example, BRCA2 more commonly than BRCA1)
- Hormone-related conditions and exogenous hormones
- Prior chest radiation and certain environmental exposures
- Age, family history, and medical comorbidities
Pathology, staging and distinctions
Most tumors in men are invasive ductal carcinomas and a higher proportion express hormone receptors (estrogen and progesterone receptors) compared with many female cases. Lobular cancers are rare because male breasts generally lack developed lobules. Staging follows the same anatomical principles used in female breast cancer (tumor size, nodal involvement, distant spread) and guides treatment decisions.
Treatment and management
Surgery is central to management; simple or modified mastectomy is commonly performed because of limited breast tissue. Sentinel lymph node biopsy or axillary dissection assesses nodal spread. Radiation therapy is used selectively. Systemic treatments include endocrine therapy (for hormone receptor–positive tumors), chemotherapy, and targeted agents when appropriate. Genetic findings such as BRCA mutations may influence systemic choices and eligibility for specific targeted drugs. Multidisciplinary care is important to tailor therapy to stage and patient health.
Prognosis, epidemiology and prevention
Because male breast cancer is uncommon, overall awareness and research have been more limited, but outcomes are broadly comparable to women when matched by stage and biology. Incidence rises with age. Men with strong family histories or known genetic mutations may benefit from genetic counseling and informed surveillance strategies. Reducing modifiable risks such as alcohol use and managing obesity or liver disease can be sensible prevention measures. For resources on occupational or radiation risks consult risk factor guidance.
Early recognition, prompt diagnostic workup, and multidisciplinary treatment planning improve the chances of successful outcomes. Men who notice a breast lump or other suspicious change should seek medical evaluation without delay.